Hartmut Beck
Drug Discovery Laboratory (Norway)(NO)Bayer (Germany)(DE)
Publications by Year
Research Areas
Computational Drug Discovery Methods, SARS-CoV-2 and COVID-19 Research, Cancer, Hypoxia, and Metabolism, interferon and immune responses, Asymmetric Synthesis and Catalysis
Most-Cited Works
- → BAY 87‐2243, a highly potent and selective inhibitor of hypoxia‐induced gene activation has antitumor activities by inhibition of mitochondrial complex I(2013)223 cited
- → Small molecules and their impact in drug discovery: A perspective on the occasion of the 125th anniversary of the Bayer Chemical Research Laboratory(2022)174 cited
- → Target 2035 – update on the quest for a probe for every protein(2021)78 cited
- → Discovery of Molidustat (BAY 85‐3934): A Small‐Molecule Oral HIF‐Prolyl Hydroxylase (HIF‐PH) Inhibitor for the Treatment of Renal Anemia(2018)75 cited
- → High Regio-, Chemo-, and Stereoselectivity via Low-Temperature 4 + 3 Cycloadditions. Convergent Synthesis of Multifunctionalized Vinylmetals (M = Si, Sn) and S-Vinyl Benzenecarbothioates(2000)46 cited
- → Potent and Selective Human Prostaglandin F (FP) Receptor Antagonist (BAY-6672) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)(2020)31 cited
- → Discovery and Characterization of BAY-805, a Potent and Selective Inhibitor of Ubiquitin-Specific Protease USP21(2023)24 cited
- → CACHE Challenge #1: Targeting the WDR Domain of LRRK2, A Parkinson’s Disease Associated Protein(2024)23 cited
- → Asymmetric Synthesis of the C1–C16 Segment of Lasonolide A(1999)20 cited
- → Target 2035 – an update on private sector contributions(2023)17 cited